Publication Date
1-1-2023
Journal
Methodist DeBakey Cardiovascular J
DOI
10.14797/mdcvj.1271
PMID
37547899
PMCID
PMC10402813
PubMedCentral® Posted Date
8-1-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, Defibrillators, Implantable, Prosthesis-Related Infections, Pacemaker, Artificial, Heart Diseases, Communicable Diseases, Bacteremia, Retrospective Studies, cardiac implantable electronic devices, bacteremia, hematogenous seeding, infective endocarditis
Abstract
More than 400,000 cardiac implantable electronic devices (CIEDs), including permanent pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy devices, are implanted every year in the United States (US). Infection is a serious complication of CIED therapy and is associated with high morbidity and mortality. While CIED pocket infection can be diagnosed based on clinical exam findings, positive blood culture may be the only manifestation of CIED lead infection. Thus, management of bacteremia in patients living with CIEDs requires special consideration. This review summarizes contemporary data in the context of the recently updated 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis. We have synthesized these data into an algorithmic approach to streamline the diagnostic evaluation of CIED infection in patients presenting with bacteremia.
Included in
Bacterial Infections and Mycoses Commons, Cardiology Commons, Cardiovascular Diseases Commons, Infectious Disease Commons, Medical Sciences Commons